Apigenin from Herbal Medicine Halts Psoriasis by Blocking a Key Cell Cycle Pathway
A natural flavonoid found in traditional Chinese herbs suppresses skin cell overproliferation and inflammation in psoriasis via the CDK2/E2F2 pathway.
Summary
Researchers identified apigenin, a flavonoid compound from the traditional Chinese herbal formula Qing Xue Wan (QXW), as a potent anti-psoriatic agent. Using mouse models and human keratinocyte cell studies, they showed that apigenin reduces skin thickening, inflammatory cell infiltration, and pro-inflammatory cytokines. Mechanistically, apigenin works by inhibiting the CDK2/E2F2 cell cycle signaling pathway and dampening IL-17 inflammatory signaling, curbing the runaway keratinocyte proliferation characteristic of psoriasis. These findings provide the first systematic pharmacological validation of a key traditional remedy and point to apigenin as its primary active ingredient.
Detailed Summary
Psoriasis affects millions worldwide and is characterized by chronic skin inflammation, immune cell infiltration, and uncontrolled proliferation of keratinocytes—the dominant skin cells. While biologic drugs have transformed treatment, interest in plant-derived compounds with anti-inflammatory and anti-proliferative properties remains high, especially for accessible or complementary therapies.
This study investigated Qing Xue Wan (QXW), a traditional Chinese medicine formula, and one of its core components, Dijincao (DJC). Mice with imiquimod-induced psoriasis were treated with QXW or DJC, and outcomes were measured using the Psoriasis Area and Severity Index (PASI), histology, immunohistochemistry, and cytokine profiling. Both treatments significantly reduced disease severity scores, skin thickness, spleen enlargement, and serum inflammatory cytokines.
Using advanced mass spectrometry (UPLC-QTOF/MS) and LPS-stimulated human HaCaT keratinocyte models, the researchers identified apigenin as the primary bioactive compound driving DJC's effects. Transcriptomic RNA sequencing, Western blotting, cell cycle analysis, and luciferase assays then revealed the mechanism: apigenin inhibits the CDK2/E2F2 axis, a key regulator of the cell cycle, preventing keratinocytes from entering uncontrolled proliferation. It also suppresses IL-17 signaling, a major inflammatory pathway in psoriasis.
The implications are meaningful. Apigenin is widely found in common foods like parsley, celery, and chamomile and has a favorable safety profile. Mechanistic validation of its CDK2/E2F2 inhibition opens a new target for topical or systemic psoriasis therapies. It also lends scientific credibility to traditional herbal formulas.
Caveats include the reliance on animal and cell-line models, with no human clinical trial data. The bioavailability and optimal dosing of apigenin in humans remain to be established. Results from imiquimod-induced murine psoriasis may not fully replicate human disease complexity.
Key Findings
- Apigenin identified as the principal active compound in traditional Chinese herbal formula DJC using mass spectrometry and cell models.
- Apigenin inhibits the CDK2/E2F2 signaling pathway, halting keratinocyte hyperproliferation central to psoriasis.
- Both QXW and DJC significantly reduced PASI scores, skin thickness, and pro-inflammatory cytokines in mice.
- IL-17 inflammatory signaling was suppressed by apigenin, targeting a clinically validated psoriasis pathway.
- First systematic pharmacological comparison of QXW, DJC, and apigenin in psoriasis models.
Methodology
IMQ-induced psoriasis mouse models were treated with QXW or DJC; outcomes assessed via PASI, histology, immunohistochemistry, RT-PCR, and ELISA. UPLC-QTOF/MS identified active compounds in DJC, validated in LPS-stimulated HaCaT human keratinocytes. Mechanistic studies employed RNA sequencing, Western blotting, cell cycle analysis, and luciferase reporter assays.
Study Limitations
All efficacy data derive from mouse models and cell lines, with no human clinical trial evidence presented. Apigenin's oral bioavailability and therapeutic dosing in humans are not addressed. The imiquimod mouse model captures some but not all aspects of human psoriasis pathophysiology.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.